FrancophonIA/ELRC3.0 huggingface dataset:
English: Plasma protein binding of maropitant in cats was estimated to be 99.1%.
Maltese: Abbinar ta' maropitant ma' proteini filplażma fil-qtates ġie stmat li hu 99.1%.
English: At a dose of 8 mg/kg, Cmax of 776 ng/ml was reached at 1.7 hours post-dosing.
Maltese: B'doża ta' 8 mg/kg, Cmax ta' 776 ng/ml intlaħqet wara 1.7 sigħat mid-doża.
English: The volume of distribution at steady-state (Vss) was 2.3 l/kg and systemic clearance was 0.51 l/h/kg.
Maltese: Il-volum ta' distribuzzjoni f'steady-state (Vss) kien 2.3 l/kg u systemic clearance kien 0.51 l/s/kg.
English: For the major metabolite 10.4% of the maropitant dose was recovered in urine and 9.3% in faeces.
Maltese: 4% ġie irkuprat fl-urina u 9.3% fl-ippurgar.
English: 1 ml of solution contains 10 mg maropitant (as maropitant citrate monohydrate).
Maltese: OĦRA 1 ml ta' soluzzjoni fiha 10 mg maropitant (bħala ċitrat ta' maropitant monoidrat)
English: The volume of distribution at steady-state (Vss) was 9.3 l/kg and systemic clearance was 1.5 l/h/kg.
Maltese: Il-volum ta' distribuzzjoni f'steady-state (Vss) kien 9.3 l/kg u systemic clearance kien 1.5 l/s/kg.
English: de Camprodon, s/n Finca La Riba
Maltese: Finca La Riba
English: EU/2/06/062/001 (16 mg tablets) EU/2/06/062/002 (24 mg tablets) EU/2/06/062/003 (60 mg tablets) EU/2/06/062/004 (160 mg tablets)
Maltese: EU/2/06/062/003 (Pilloli ta' 60 mg) EU/2/06/062/004 (Pilloli ta' 160 mg)
English: The elimination t1/2 following intravenous dosing was approximately 5.8 h.
Maltese: L- elimination t1/2 wara doża fil-vina kien bejn wieħed u ieħor 5.8 sigħat.
English: Date of first authorisation: 29/09/2006.
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI / TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 29/09/2006
English: The tablets also contain Sunset Yellow (E110) as a colorant.
Maltese: Il-pilloli fihom ukoll Sunset Yellow (E110) bħala kolorant.
English: The elimination halflife at 8 mg/kg was 5.47 hours.
Maltese: Il-half-life ta' eliminazzjoni b'8 mg/kg kien 5.47 sigħat.
English: Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t0.5) of 4.03 hours.
Maltese: L-ogħla konċentrazzjonijiet ġew segwiti minn tnaqqis sistemiku b'half-life ta' eliminazzjoni apparenti (t0.5) ta' 4.03 sigħat.
English: In very rare cases, anaphylactic type reactions (allergic oedema, urticaria, erythema, collapse, dyspnoea, pale mucous membranes) may occur.
Maltese: F'każijiet rari ħafna jistgħu jseħħu reazzjonijiet tat-tip anafilattiku (edema allerġika, urtikarja, eritema, kollass, dyspnoea, membrani mukożi pallidi).
English: The anti-emetic efficacy of maropitant against central and peripheral emetics was demonstrated in experimental studies including apomorphine, cisplatin and syrup of ipecac (dogs) and xylazine (cats).
Maltese: L-effett anti-emetiku ta' maropitant ġie ddimostrat fi studji sperimentali kontra emetiċi ċentrali u periferali li jinkludu apomorphine, cisplatin u ġulepp ta' ipecac (klieb) u xlazine (qtates).
English: Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 8.84 hours.
Maltese: L-ogħla konċentrazzjonijiet ġew segwiti minn tnaqqis sistemiku b'half-life apparenti ta' eliminazzjoni (t1/2ta' 8.84 siegħat.
English: Manufacturer responsible for batch release: FAREVA AMBOISE Zone Industrielle,
Maltese: Manifattur responsabbli għall-ħrug tal-lott: FAREVA AMBOISE
English: In laboratory studies, maropitant has been shown to be a potential eye irritant.
Maltese: Studji f'laboratorju wrew li maropitant jista' jkun irritanti għall-għajnejn.
English: With the extended use of Cerenia tablets in dogs from 5 to 14 consecutive days, the periodic safety update report (PSUR) cycle for Cerenia has been reset and the data lock point for the next PSUR is 30 June 2014 for submission of 6 monthly reports (covering all authorised presentations of the product) for the next two years, followed by yearly reports for the subsequent two years and thereafter at 3 yearly intervals.
Maltese: Bl-użu estiż ta' Cerenia pilloli għal klieb minn 5 sa 14-il ġurnata konsekuttiva, ċ-ċiklu tal-periodic safety update report (PSUR) għal Cerenia ġie rrisettjat u d-data lock point għall-PSUR li jmiss hi 30 Ġunju 2014 b'sottomissjoni ta' rapport kull 6 xhur (li jkopru il-presentazzjonijiet awtorizzati kollha) għas-sentejn li ġejjin, segwiti minn rapport kull sena għas-sentejn ta' wara u rapport kull 3 snin fissnin ta' wara.
English: This centre consists of several brainstem nuclei (area postrema, nucleus tractus solitarius, dorsal motor nucleus of the vagus) that receive and integrate sensory stimuli from central and peripheral sources and chemical stimuli from the circulation and the cerebro-spinal fluid.
Maltese: Dan iċċentru jikkonsisti minn ħafna nuklei tal-brainstem (area postrema, nukleus tractus solitarius, dorsal motor nukleus tal-vagus) li jirċievu u jintegraw stimuli sensorjali minn sorsi ċentrali u periferali u stimuli kimiċi miċ-ċirkulazzjoni u l-likwidu ċerebro-spinali.
English: Maropitant is a neurokinin 1 (NK1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family.
Maltese: Maropitant huwa antagonist ta' neurokinin (NK1) receptor, li jaħdem billi ma jħallix l-abbinar ta' substance P, neuropeptide tal-familja tachykinin.
English: Dog body weight (kg)
Maltese: Piż tal-Kelb (kg)
English: Cerenia 16 mg tablets for dogs Cerenia 24 mg tablets for dogs Cerenia 60 mg tablets for dogs Cerenia 160 mg tablets for dogs
Maltese: Cerenia 16 mg pilloli għal klieb Cerenia 24 mg pilloli għal klieb Cerenia 60 mg pilloli għal klieb Cerenia 160 mg pilloli għal klieb
English: Cerenia 16 mg tablets for dogs Cerenia 24 mg tablets for dogs Cerenia 60 mg tablets for dogs Cerenia 160 mg tablets for dogs maropitant
Maltese: Cerenia 16 mg pilloli għal klieb Cerenia 24 mg pilloli għal klieb Cerenia 60 mg pilloli għal klieb Cerenia 160 mg pilloli għal klieb maropitant
English: Cerenia tablets are available in 16 mg, 24 mg, 60 mg and 160 mg strength.
Maltese: Pilloli Cerenia jiġu b'saħħa ta' 16 mg, 24 mg, 60 mg u 160 mg.
English: SC, IV
Maltese: MOD(I) TA' AMMINISTRAZZJONI SC, IV
English: Maropitant (as maropitant citrate monohydrate)
Maltese: Lactose monohydrate
English: The inter-individual variation in kinetics may be large, up to 70 CV% for AUC.
Maltese: Il-varjazzjoni fil-kinetika minn individwu għal ieħor tista' tkun kbira, sa 70 CV% għal AUC.
English: Each tablet contains 16 mg, 24 mg, 60 mg or 160 mg maropitant as maropitant citrate monohydrate.
Maltese: Kull pillola fiha 16 mg, 24 mg, 60 mg jew 160 mg maropitant bħala ċitrat ta' maropitant monoidrat.
English: The volume of distribution at steady-state (Vss) determined after intravenous administration at 1-2 mg/kg ranged from approximately 4.4 to 7.0 l/kg.
Maltese: Ilvolum ta' distribuzzjoni fi steady-state (Vss) imkejjel wara amministrazzjoni fil-vina b'1 - 2 mg/kg varja bejn wieħed u ieħor minn 4.4 sa 7.01 l/kg.
English: METHOD AND ROUTE(S) OF ADMINISTRATION
Maltese: METODU U MOD(I) TA' AMMINISTRAZZJONI SC, IV
English: Maropitant displays non-linear pharmacokinetics (AUC increases more than proportionally with increasing dose) when administered orally within the 1-16 mg/kg dose range.
Maltese: Maropitant kellu xejriet farmakokinetiċi li mhumiex linjari (AUC jiżdied aktar minn proporzjonalment ma' żieda fid-doża) meta amministrat mill-ħalq f'doża ta' bejn 1 - 16 mg/kg.
English: In vivo studies in dogs demonstrated the anti-emetic efficacy of maropitant against central and peripheral emetics including apomorphine, cisplatin and syrup of ipecac.
Maltese: Fi studji in vivo fil-klieb l-effett antiemetiku ta' maropitant ġie ddimostrat kontra emetiċi ċentrali u periferali li jinkludu apomorphine, cisplatin u ġulepp ta' ipecac.
English: Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 363 ng/ml.
Maltese: Wara doża waħda fil-vina ta' 1 mg/kg il-konċentrazzjoni inizjali fil-plażma kienet ta' 363 ng/ml.
English: • For the prevention of perioperative nausea and vomiting and improvement in recovery from general anaesthesia after use of the μ-opiate receptor agonist morphine.
Maltese: • Għall-prevenzjoni ta' nawżja u remettar waqt l-operazzjoni u titjib fl-irkupru mill-anestesija ġenerali wara l-użu tal-morfina li hija μ-opiate receptor agonist.
English: Amber molded glass type 1 vial, 20 ml, chlorobutyl rubber stopper and aluminium overseal with flip-off button.
Maltese: In-natura u l-għamla tal-ippakkjarli jmiss mall-prodott Kunjett kannella tal-ħġieġ iffurmat ta' Tip 1, 20 ml, tapp tal-klorobutil u siġill fuq kollox tal-aluminju b'buttuna flip-off.
English: Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 16.8 hours.
Maltese: Logħla konċentrazzjonijiet ġew segwiti minn tnaqqis sistemiku b'half-life apparenti ta' eliminazzjoni (t½) ta' 16.8 sigħat.
English: Croscarmellose sodium Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sunset Yellow (E110) as a colorant
Maltese: Magnesium stearate Microcrystalline cellulose
English: Plasma protein binding of maropitant in dogs is more than 99%.
Maltese: Abbinar ta' maropitant ma' proteini fil-plażma fil-klieb huwa ta' aktar minn 99%.
English: The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 92 ng/ml; this was achieved within 0.75 hours post-dosing (Tmax).
Maltese: Il-profil farmakokinetiku ta' maropitant wara li ġie amministrat f'doża waħda ta' 1 mg/kg piż taħt ilġilda lil klieb, kien ikkaraterizzat minn konċentrazzjoni massima (Cmax) fil-plażma ta' bejn wieħed u ieħor 92 ng/ml; din intlaħqet fi żmien 0.75 siegħa wara d-doża (Tmax).
English: Cerenia 10 mg/ml injection for dogs and cats maropitant
Maltese: VETERINARJU Cerenia 10 mg/ml injezzjoni għal klieb u qtates maropitant
English: Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 1040 ng/ml.
Maltese: Wara doża waħda fil-vina ta' 1 mg/kg il-konċentrazzjoni inizjali fil-plażma kienet ta' 1040 ng/ml.
English: Cerenia should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.
Maltese: Cerenia m'għandhiex tintuża flimkien ma' Ca-channel antagonists billi maropitant għandu affinità għal Ca-channels.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Maltese: Informazzjoni dettaljata dwar dan il-prodott mediku veterinarju tinstab fuq il-websajt tal-Aġenzija Ewropea dwar il-Mediċini http://www.ema.europa.eu/ 15.
English: Maropitant is a potent and selective neurokinin (NK-1) receptor antagonist, which acts by inhibiting the binding of substance P, a neuropeptide of the tachykinin family, in the CNS.
Maltese: Maropitant huwa antagonist qawwi u selettiv ta' neurokinin (NK-1) receptor, li jaħdem billi ma jħallix l-abbinar fis-sistema nervuża ċentrali ta' substance P, neuropeptide tal-familja tachykinin.
English: Use only according to the benefit-risk assessment by the responsible veterinarian.
Maltese: Uża biss skont ilvalutazzjoni tal-benefiċċju u r-riskju tal-veterinarju responsabbli.
English: Each tablet contains 24 mg maropitant as maropitant citrate monohydrate.
Maltese: Kull pillola fiha 24 mg maropitant bħala ċitrat ta' maropitant monoidrat.
English: Maropitant displays linear kinetics when administered subcutaneously within the 0.25-3 mg/kg dose range.
Maltese: 3%. Maropitant kellu xejriet farmakokinetiċi linjari meta amministrat taħt il-ġilda f'doża ta' bejn 0.25 - 3 mg/kg.
English: Renal and faecal clearances are minor routes of elimination for maropitant, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine or faeces as maropitant.
Maltese: Clearance mill-kliewi u mal-ippurgar huwa mod minuri ta' eliminazzjoni, b'anqas minn 1% ta' doża ta' 1 mg/kg taħt il-ġilda titfaċċa fl-urina jew fl-ippurgar bħala maropitant.
English: Maropitant undergoes cytochrome P450 (CYP) metabolism in the liver.
Maltese: Maropitant jiġi metabolizzat fil-fwied permezz ta' cytochrome P450 (CYP). CYP2D15 u CYP3A12 kienu identifikati bħala l-forom fil-qtates involuti filbijotrasformazzjoni ta' maropitant fil-fwied.
English: A variety of in vitro assays have demonstrated that maropitant binds selectively at the NK1 receptor with dose-dependent functional antagonism of substance P activity.
Maltese: Varjetà ta' studji in vitro wrew li maropitant jabbina b'mod selettiv ma' NK1 receptor u jantagonizza l-attività ta'substance P b'mod dipendenti fuq id-doża.
English: Each tablet contains 160 mg maropitant as maropitant citrate monohydrate.
Maltese: Kull pillola fiha 160 mg maropitant bħala ċitrat ta' maropitant monoidrat.
English: The pharmacokinetic profile of maropitant when administered as a single oral dose of 2 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 81 ng/ml; this was achieved within 1.9 hours post-dosing (Tmax).
Maltese: Il-profil farmakokinetiku ta' maropitant wara li ġie amministrat f'doża waħda ta' 2 mg/kg piż millħalq lil klieb, kien karaterizzat minn konċentrazzjoni massima (Cmax) fil-plażma ta' bejn wieħed u ieħor 81 ng/ml; din intlaħqet fi żmien 1.9 sigħat wara d-doża (Tmax).
English: Zoetis (Logo)
Maltese: INDIKAZZJONI(JIET)
English: Interaction with other medicinal products and other forms of interaction: Cerenia should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.
Maltese: .8 Interazzjoni ma' prodotti mediċinali oħra jew forom oħra ta' interazzjoni Cerenia m'għandhiex tintuża flimkien ma' Ca-channel antagonists billi maropitant għandu affinità għal Ca-channels.
English: Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 250%.
Maltese: Wara amministrazzjoni ripetuta taħt il-ġilda għal ħamest ijiem wara xulxin b'doża darba kuljum ta' 1 mg/kg, l-akkumular kien 250%.
English: Cerenia tablets are supplied in blister packs with four tablets per pack.
Maltese: Pilloli Cerenia jiġu f'folji b'erba' pilloli f'kull pakkett.
English: Following repeated oral administration for five consecutive days at a daily dose of 2 mg/kg, accumulation was 151%.
Maltese: Wara amministrazzjoni ripetuta mill-ħalq għal ħamest ijiem wara xulxin b'doża darba kuljum ta' 2 mg/kg, l-akkumular kien 151%.
English: It also contains metacresol (as preservative).
Maltese: Fiha wkoll metacresol (bħala preservattiv).
English: Renal clearance is a minor route of elimination, with less than 1% of an 8 mg/kg oral dose appearing in the urine as either maropitant or its major metabolite.
Maltese: Clearance mill-kliewi huwa mod minuri ta' eliminazzjoni, b'anqas minn 1% ta' doża ta' 8 mg/kg millħalq titfaċċa fl-urina bħala maropitant jew il-forma maġġuri tiegħu.
English: In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products in the same syringe.
Maltese: Fin-nuqqas ta' studji dwar kompattibilità, dan il-prodott mediċinali veterinarju ma jistax jintuża flimkien ma' prodotti mediċinali veterinarji oħra.
English: As maropitant is accumulated in the body during a 14-day treatment period due to metabolic saturation, careful monitoring of liver function in addition to any adverse events should be implemented during long term treatment.
Maltese: Billi maropitant jakkumula fil-ġisem waqt perjodu ta' trattament ta' 14-il ġurnata minħabba f'saturazzjoni metabolika, waqt trattament fit-tul għandu jiġi implimentat monitoraġġ attent tal-funzjoni tal-fwied flimkien ma' effetti oħra mhux mixtieqa.
English: Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 146%.
Maltese: Wara amministrazzjoni ripetuta taħt il-ġilda għal ħamest ijiem wara xulxin b'doża darba kuljum ta' 2 mg/kg, l-akkumular kien 146%.
English: Apart from transient reactions at the injection site following subcutaneous administration, Cerenia solution for injection was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration).
Maltese: Apparti reazzjonijiet li jgħaddu fil-post tal-injezzjoni wara amministrazzjoni taħt il-ġilda, soluzzjoni għall-injezzjoni Cerenia kienet ittollerata sew fi klieb u qtates żgħar injettati b'sa 5 mg/kg (ħames darbiet aktar mid-doża rikmandata) għal 15-il ġurnata wara xulxin (3 darbiet aktar miż-żmien rakkomandat ta' amministrazzjoni).
English: Following repeated oral administration for two consecutive days at a daily dose of 8 mg/kg, accumulation was 218%.
Maltese: Wara amministrazzjoni ripetuta mill-ħalq għal jumejn wara xulxin b'doża darba kuljum ta' 8 mg/kg, l-akkumular kien 218%.
English: EXP {month/year} Once broached, use by:………..
Maltese: JISKADI {xahar/sena} Ladarba jittaqqab, uża sa':.................
English: Each tablet contains 16 mg maropitant as maropitant citrate monohydrate.
Maltese: Kull pillola fiha 16 mg maropitant bħala ċitrat ta' maropitant monoidrat.
English: Maropitant displays linear kinetics when administered subcutaneously within the 0.5-2 mg/kg dose range.
Maltese: 7 Maropitant kellu xejriet farmakokinetiċi linjari meta amministrat taħt il-ġilda f'doża ta' bejn 0.5 - 2 mg/kg.
English: Vomiting is a complex process coordinated centrally by the emetic centre.
Maltese: Remettar huwa proċess kompless li jiġi kkordinat miċ-ċentru emetiku tas-sistema ċentrali.
English: Solution for injection.
Maltese: Anti-emetiċi.
English: Cerenia solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight).
Maltese: Soluzzjoni għall-injezzjoni Cerenia għandha tiġi injettata taħt il-ġilda jew fil-vina, darba kuljum, f'doża ta' 1 mg/kg piż (1 ml/10 kg piż).
English: Each tablet contains 60 mg maropitant as maropitant citrate monohydrate.
Maltese: Kull pillola fiha 60 mg maropitant bħala ċitrat ta' maropitant monoidrat.
English: Renal clearance is a minor route of elimination, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine as either maropitant or its major metabolite.
Maltese: Clearance mill-kliewi huwa mod minuri ta' eliminazzjoni, b'anqas minn 1% ta' doża ta' 1 mg/kg taħt il-ġilda titfaċċa fl-urina bħala maropitant jew il-forma maġġuri tiegħu.
English: Increases of approximately 10% in the QT interval of the ECG were observed in a study on healthy beagle dogs administered 8 mg/kg orally; however, such an increase is unlikely to be of clinical significance.
Maltese: Fi studju fuq klieb f'saħħithom tar-razza beagle instab li kien hemm żieda ta' bejn wieħed u ieħor 10% fl-intervall QT meta ġew amministrati 8 mg/kg mill-ħalq; madankollu din iż-żieda m'għandux ikollha sinifikat kliniku.
English: Maropitant is highly bound to plasma proteins and may compete with other highly bound medicines.
Maltese: Maropitant jabbina b'mod qawwi ma' proteini fil-plażma u jista' jikkompeti ma' mediċini oħra li jabbinaw b'mod qawwi wkoll.
English: During clinical studies maropitant plasma levels conferred efficacy from 1 hour after administration.
Maltese: Waqt studji kliniċi l-livelli ta' maropitant fil-plażma bdew jgħatu effett siegħa wara l amministrazzjoni.
English: Dogs
Maltese: Zoetis
English: The elimination t1/2 following intravenous dosing was approximately 4.9 h. There appears to be an age-related effect on the pharmacokinetics of maropitant in cats with kittens having higher clearance than adults.
Maltese: L- elimination t1/2 wara doża fil-vina kien bejn wieħed u ieħor 4.9 sigħat.
English: CYP2D15 and CYP3A12 were identified as the canine isoforms involved in the hepatic biotransformation of maropitant.
Maltese: Maropitant jiġi metabolizzat fil-fwied permezz ta' cytochrome P450 (CYP). CYP2D15 u CYP3A12 kienu identifikati bħala l-forom fil-klieb involuti fil-bijotrasformazzjoni ta' maropitant fil-fwied.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box / Tablets
Maltese: Kaxxa tal-kartun / Pilloli
English: A. LABELLING
Maltese: (Marka)
English: Good veterinary practice indicates that antiemetics should be used in conjunction with other veterinary and supportive measures, such as dietary control and fluid replacement therapy while addressing the underlying causes of the vomiting.
Maltese: Prattika veterinarja tajba titlob li mediċini kontra remettar għandhom jintużaw flimkien ma' miżuri oħra ta' għajnuna, bħal kontroll tad-dieta u ‘fluid replacement therapy' waqt li jiġu indirizzati l-kawżi ta' remettar.
English: Cerenia tablets should not be administered wrapped or encapsulated in food as this may delay dissolution of the tablet and consequently the onset of the effect.
Maltese: Soluzzjoni għall-injezzjoni Cerenia tista' tingħata għal sa ħamest-ijiem u pilloli Cerenia għal sa erbatax-il ġurnata.
English: • For the treatment and prevention of nausea induced by chemotherapy.
Maltese: • Għat-trattament u prevenzjoni ta' nawżja kkawżat mill-kimoterapija.
English: By inhibiting the binding of substance P within the emetic centre, maropitant is effective against neural and humoral (central and peripheral) causes of vomiting.
Maltese: Billi ma jħallix l-abbinar ta' substance P fiċ-ċentru emetiku, maropitant huwa effettiv kontra remettar ikkawżat b'mod newrali u ħumorali (ċentrali u periferali).
English: Substance P is found in significant concentrations in the nuclei comprising the emetic centre and is considered the key neurotransmitter involved in vomiting.
Maltese: Substance P tinstab f'konċentrazzjonijiet sinifikattivi fin-nuklei li jiffurmaw iċ-ċentru emetiku u hija kkunsidrata n-newrotrażmettitur l-aktar importanti involuta fir-remettar.
English: Cerenia solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg/kg bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days.
Maltese: Cerenia soluzzjoni għall-injezzjoni għandha tiġi injettata taħt il-ġilda jew fil-vina, darba kuljum, f'doża ta' 1 mg/kg piż (1 ml/10 kg piż) sa ħamest ijiem wara xulxin.
English: The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to cats was characterised by a maximum concentration (Cmax) in plasma of approximately 165 ng/ml; this was achieved on average 0.32 hours (19 min) post-dosing (Tmax).
Maltese: Il-profil farmakokinetiku ta' maropitant wara li ġie amministrat f'doża waħda ta' 1 mg/kg piż taħt ilġilda lil qtates, kien ikkaraterizzat minn konċentrazzjoni massima (Cmax) fil-plażma ta' bejn wieħed u ieħor 165 ng/ml; din intlaħqet fi żmien medju ta' 0.
English: Pharmacotherapeutic group: Antiemetics.
Maltese: Grupp farmakoterapewtiku:
English: Cerenia 10 mg/ml solution for injection for dogs and cats is available in 20 ml amber glass vials.
Maltese: VETERINARJU Cerenia 10 mg/ml soluzzjoni għall-injezzjoni għal klieb u qtates.
English: • Firstly, fold or cut along the perforation between each tablet as shown by the scissor symbol 
Maltese: • L-ewwel itwi jew aqta' mal-perforazzjoni li hemm bejn il-pilloli kif juri s-simbolu tal-imqass
English: To treat and/or prevent vomiting except motion sickness, Cerenia tablets should be administered once daily, at a dose of 2 mg maropitant per kg bodyweight, using the number of tablets given in the table below.
Maltese: Għat-trattament u l-prevenzjoni ta' remettar, il-pilloli Cerenia għandhom jiġu amministrati darba kuljum f'doża ta' 2 mg maropitant għal kull kg piż tal-ġisem, b'numru ta' pilloli kif jidher fit-tabella hawn taħt.
English: The anti-emetic effect persists for at least 12 hours, which for convenience may allow administration the night before early morning travel.
Maltese: L-effett anti-emetiku jdum għal tal-anqas 12-il siegħa, u b'hekk għall-konvenjenza, il-kura tista' tiġi amministrata l-lejl ta' qabel vjaġġ kmieni filgħodu.